CTH-302
Phase III trial looking at the use of sublingual apomorphine in patients with advanced Parkinson’s Disease. Sponsor: Sunovion. Currently recruiting.
Contact: aleksandra.podlewska@nhs.net
RECRUITMENT CURRENTLY ON HOLD DUE TO PANDEMIC
Duoglobe (P14-494)
DUOdopa/Duopa in Patients with Advanced Parkinson’s Disease (PD) – a GLobal Observational Study Evaluating Long-Term Effectiveness (DUOGLOBE).
A global multicentre single-arm observational study to assess the effectiveness of levodopa/carbidopa intestinal gel treatment on OFF time as reported by advanced PD patients. The study period is split as [1] baseline, [2] treatment with PEG-J vistit and titration period of up to 14 days, and [3] up to 36 months observations.
RECRUITMENT CURRENTLY ON HOLD DUE TO PANDEMIC
Theravance 0169
Phase 3, 4-week, Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure Participants are randomised to ampreloxetine or placebo and will recieve a single, oral daily dose of active or placebo drug for 4 weeks.
RECRUITMENT CURRENTLY ON HOLD DUE TO PANDEMIC
M15-741
A 52-week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects with Parkinson’s disease. This phase 3 open label study is using this new form of LD/CD (ABBV-951) which is a novel form of administering the medication.
RECRUITMENT CURRENTLY ON HOLD DUE TO PANDEMIC
NeuroDerm (ND0612-317)
A phase-3 RCT – active-controlled, double-blind, double-dummy, parallel group trial to determine the effect of ND0612 on daily “ON” time without troublesome dyskinesia (defined as the sum of “ON” time without dyskinesia and “ON” time with non-troublesome dyskinesia) using subject-completed “ON/OFF” diary assessments of motor function in subjects with Parkinson’s disease (PD) experiencing motor fluctuations
RECRUITMENT CURRENTLY ON HOLD DUE TO PANDEMIC
